Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)

Hemodialysis Clinical Trial

— ICON-HP  

Official title:

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03664141
• Other study ID #: Assaf Harofeh MC
• Status: Withdrawn
• Phase: Phase 3
• Start date: September 15, 2018
• Est. completion date: October 15, 2019

Study information

• Verified date: September 2018
• Source: Assaf-Harofeh Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will be performed in two parts: 1) The pharmacokinetic (PK) part and 2) The appetite and nutritional evaluation part. The PK part of study will be conducted in open label manner on 10 end stage kidney disease (ESKD) patients receiving maintenance hemodialysis (MHD) treatment. For the PK part, a starting dose of cannabis oil -1 drop of 3% cannabis oil once a day [each drop contain 1.2 mg CBD (cannabidiol) and 1.2 mg of ∆9-THC (∆9-tetrahydrocannabinol)], was judged to be safe for a first-in-MHD patient's administration. Escalation to the next higher dose and any dose adjustments of the next dose levels will be based on safety and tolerability results of the previously administered dose and available PK data of previous dose groups. Once the first dosage proved to be safe, there will be a 2 fold increase from the first dose level (2 drops once a day) to the second dose level. The dose levels will be increased by 2-fold from the previous dose level, until basal hunger and prospective consumption ratings assessed by the visual analogue scale (VAS) will increase at least by 10 mm between screening and the study visits (change-from-baseline) . PK parameters will be evaluated after first dosage administration and after dosage increased. The appetite and nutritional evaluation part of study will be conducted as a 3-month, double-blind, parallel-group, placebo-controlled, single center study. The study population will include 30 ESKD patients receiving MHD treatment with different degrees of protein-energy wasting (PEW) defined as malnutrition-inflammation score (MIS) above 6. A total of 30 subjects will be randomized to treatment with either cannabis oil or matching placebo.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 15, 2019
• Est. primary completion date: August 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, age > 18 years, on MHD hemodialysis treatment at least 3 months
• Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V > 1.2 and/or hemodialysis performed 4 hours 3 times weekly
• Patients with Malnutrition-Inflammation Score (MIS) = 6
• Informed consent obtained before any trial-related activities

Exclusion Criteria:

• Previous or current use in cannabis or marijuana
• Critical illness as defined by the need of respiratory or circulatory support
• Known or suspected allergy to trial products
• Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using contraceptive methods
• Patients with active malignant disease or liver cirrhosis
• Actively symptomatic gastrointestinal bleeding and inflammatory bowel disease
• Patients on chronic treatment with steroids on doses > 10 mg/day Prednisone (or equivalent)
• Patients treated with immunosuppressive agents
• Patients receiving any of the following medications: Astemizole, Cisapride, Pimozide or Terfenadine
• Patients suffering from:
• Acute vasculitis
• Severe systemic infections
• Severe Heart failure (NYHA class IV)
• Severe hepatic disease, defined as ALT or AST levels >3 times upper normal range
• Mental incapacity, unwillingness or language barrier
• Any condition judged by the investigator to interfere with trial participation or evaluation of results or to be potentially hazardous to the patient
• A significant history of alcohol, drug or solvent abuse
• History of schizophrenia, affective disorder, history of psychiatric hospitalization and diagnosed anxiety disorder
• The receipt of any investigational drug within 1 month prior to initiating of this study
• Scheduled renal transplantation (fixed date).

Related Conditions & MeSH terms

• Appetite Disorders
• Feeding and Eating Disorders
• Hemodialysis
• Malnutrition
• Marijuana Abuse
• Protein-Energy Malnutrition

Intervention

Drug:
• Cannabis oil
Treatment with cannabis oil
• Placebo/ Regular Oil
Treatment with placebo (Regular Oil)

Locations

Country	Name	City	State
Israel	Asaf ha Rofeh, MC	Zrifin

Sponsors (2)

Lead Sponsor	Collaborator
Assaf-Harofeh Medical Center	Tikun Olam

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall incidence and prevalence of adverse events	Overall incidence and prevalence of adverse events	For 5 months from the day of randomization
Primary	Change in appetite assessed by the Visual Analogue Scale (VAS).	VAS, 100 mm in length with words anchored at each end, expressing the most positive (=100) and the most negative rating (=0), will be used to assess specific domains of appetite separately: hunger, satiety, fullness, prospective food consumption. Each domain will be measured by the 0-100mm scale as mentioned above.	For 5 months from the day of randomization
Secondary	Change in nutritional status assessed by the Malnutrition-Inflammation Score (MIS).	MIS consists of four sections (nutritional history, physical examination, body mass index [BMI], and laboratory values) and 10 components. Each MIS component has four levels of severity from 0 (normal) to 3 (very severe). The sum of all 10 components results in an overall score ranging from 0 (normal) to 30 (severely malnourished).	For 5 months from the day of randomization
Secondary	Change in Health Related Quality of Life assessed by short form 36 (SF-36) quality of life (QoL) scoring system	SF-36 consists of 36 questions, 35 of which are compressed into eight multi-item scales: (1) physical functioning; (2) role-physical (3) bodily pain ; (4) general health; (5) vitality ; (6) social functioning (7) role-emotional and (8) mental health. In the SF36 scoring system, the scales are assessed quantitatively, each on the basis of answers to two to ten multiple choice questions, and a score between 0 and 100 is then calculated on the basis of well-defined guidelines, with a higher score indicating a better state of health.	For 5 months from the day of randomization